livea glp-1 New GLP-1 Pill Foundayo (Orforglipron)

Visualizing data through charts and graphs can make trends more apparent, aiding in the interpretation of results and the refinement of future research protocols

Retrieved from Wilding, J., Batterham, R

While it still has benefits, newer technologies are changing the game entirely

LLY also announced in mid-February 2024 that a phase 2 trial evaluating tirzepatide for liver disease metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), met its primary endpoint where up to 74% of participants achieved resolution of MASH with no worsening of fibrosis, compared to 13% on placebo